News Daily News Pfizer Discontinues Investigational PCSK9 Inhibitor Bococizumab Michael O'Riordan November 01, 2016
News Conference News TCT 2016 YELLOW II: Improved Cholesterol Efflux Linked to Plaque Stabilization in Statin-Treated Patients Michael O'Riordan October 29, 2016
News Daily News FH Screening Started at Time of Childhood Immunization Feasible and Effective Michael O'Riordan October 28, 2016
News Daily News La AHA Facilita las Interacciones Farmacológicas entre Estatinas y Fármacos contra la Enfermedad Cardiovascular Michael O'Riordan October 18, 2016
News Daily News AHA Provides Guidance on Drug-Drug Interactions With Statins and CVD Medications Michael O'Riordan October 18, 2016
News Daily News Pharmacist Management of High Cholesterol Gets More Patients to Goal, Lowers LDL Levels: RxACT Michael O'Riordan September 29, 2016
News Daily News Lowering LDL With Statins and Other Selected Agents Should Be Focus of CVD Risk Reduction, Analysis Implies Michael O'Riordan September 27, 2016
News Daily News CAC Screening Stratifies CVD Event Risk in Statin-Eligible Patients: Heinz Nixdorf Recall Study Michael O'Riordan September 22, 2016
News Daily News Guerra de los Medios Británicos: BMJ, Lancet Siguen Recortando el Uso de Estatinas Todd Neale September 19, 2016
News Daily News Battle of the Brits: BMJ, Lancet Continue Sniping Over Statins Todd Neale September 19, 2016
News Daily News Many Guidelines, Mixed Consensus: Different CVD Risk Guidelines Cause Confusion in Practice Michael O'Riordan September 16, 2016
News Daily News Demasiados Elementos en Juego: La Existencia de Diferentes y Discordantes Directrices Hace que la Valoración del Riesgo de ECV sea Confusa Michael O'Riordan September 16, 2016
News Daily News Review Touts Benefits of Statins, Seeks to Dispel Safety Concerns Todd Neale September 12, 2016
News Conference News ESC 2016 Ezetimibe Plus Pitavastatin Fails to Lower Risk of CVD Events in ACS Patients: HIJ-PROPER Michael O'Riordan August 30, 2016
News Daily News More Bang, Less Buck: Cost-Effectiveness Analysis Says Price of PCSK9 Inhibitors Needs to Drop by Two-Thirds Yael L. Maxwell August 29, 2016
News Daily News Más con Menos: Un Análisis de Rentabilidad Dice que Hay que Reducir en Dos Tercios el Precio de PCSK9 Yael L. Maxwell August 29, 2016